Tricuspid Valve Interventions Patents: Who Leads, Where the Gaps Are 2026
- Concentrated at the top. The five leading assignees hold 74.8% of all 119 records in scope, and the top ten account for every record in the ranking.
- Filing has picked back up. Annual filings ran from 1 in 2021 to 2 in 2024, a +100% rise over that span, after a peak of 21 in 2018.
- Almost everything sits under implants. A61F (implants & prostheses) touches 97.5% of records, while diagnosis and surgical technique (A61B) and body-fluid devices (A61M) trail well behind.
Filing growth compares 2021 (1 records) with 2024 (2) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 119 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This review covers 119 published patent records filed between 2015 and mid-2026 that describe tricuspid valve intervention devices and methods, drawn from filings that combine repair or annuloplasty terms with technical features such as annular dilation, lead interference, coaptation gap management, anchor placement, right ventricle function and device migration. The scope is narrow by design: it isolates documents that address the specific mechanical and physiological problems of tricuspid repair rather than valve replacement generally.
Publication trails filing by roughly 18 months, so counts for 2025 and 2026 are still incomplete and should not be read as a slowdown. The picture that follows is best read as a map of where claim space is dense, where it thins out, and which assignees have staked the largest positions.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 119 records: how filing activity has moved year over year, and which IPC subclasses the claims fall into.
Filing trend
Filings peaked at 21 in 2018, fell back over the following years, and show renewed growth from 2021 (1 filing) to 2024 (2 filings), a +100% rise over that three-year window. 2025 and 2026 figures are still filling in given the publication lag and should not be read as a decline.
Technology composition
A61F (implants & prostheses) appears in 97.5% of the 119 records, confirming that most filings claim a physical device rather than a pure method. A61B (diagnosis & surgery) appears in 42.0%, A61M (body-fluid devices) in 20.2%, with G06T (imaging) and A61L (sterilising) each below 6%. Because records can carry multiple classes, these shares add to more than 100% and should be read against the 119-record total, not against each other.
Shares are the percentage of the 119 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Tricuspid Valve Interventions with Eureka
This page is one run against one query. Ask Eureka your own question about tricuspid valve interventions and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records in this field
Method and System for Performing Mitral and Tricuspid Annuloplasty (US20250325371A1)
A method for performing a mitral or tricuspid annuloplasty and forming a support system within the heart. The method punctures the posterior sulcus via catheter to create a central support point, captures the guidewire in the left atrium, places additional anchor devices with ropes on each side, and couples the resulting bars with a zipper mechanism to complete the support structure.Filed by Condado, Jose A; published 23 October 2025.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20130325110A1 | Systems and methods for placing a coapting member between valvular leaflets | 477 |
| 2 | US20130338763A1 | Devices and methods for reducing cardiac valve regurgitation | 225 |
| 3 | US20180146966A1 | Tricuspid valve repair system | 175 |
| 4 | US9474605B2 | Devices and methods for reducing cardiac valve regurgitation | 167 |
| 5 | US20170035561A1 | Devices for reducing cardiac valve regurgitation | 150 |
| 6 | US20150025553A1 | Right ventricular papillary approximation | 129 |
| 7 | EP2849681A1 | Devices and methods for reducing cardiac valve regurgitation | 75 |
| 8 | WO2013173587A1 | Devices and methods for reducing cardiac valve regurgitation | 72 |
| 9 | EP2849680A2 | Systems and methods for placing a coapting member between valvular leaflets | 66 |
| 10 | US9636223B2 | Systems and methods for placing a coapting member between valvular leaflets | 64 |
Ranked by citation count within this corpus; older filings accumulate citations over time, so this favours foundational documents over recent ones.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for strategy
Three patterns worth acting on before drafting new claims or scoping freedom-to-operate work in this space.
The field has consolidated early
Five assignees hold nearly three-quarters of all published records, and the top ten account for the entire ranked set. A new entrant is filing into territory that a small group has already mapped closely, particularly around anchor placement and annular dilation mechanisms.
Physical device claims dominate over method claims
Almost every record in scope claims an implant or prosthesis component. Diagnosis and surgical-technique claims (A61B, 42.0%) and body-fluid handling claims (A61M, 20.2%) are present but secondary, suggesting device geometry and anchoring mechanics are the primary battleground.
Activity is picking back up after the mid-cycle dip
After the 2018 peak of 21 filings, annual counts fell before recovering from 1 in 2021 to 2 in 2024. That is a small base, but it points to renewed interest rather than an exhausted field, especially once 2025-2026 filings finish publishing.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to tricuspid valve interventions, with the prior art for and against each one.
Who holds the claim space, and where it thins out
The ranked leaders cover the entire top ten by record count, but recent-year filing activity shows the pace has slowed across most of them even as the field as a whole shows renewed growth.
A single assignee holds the largest single share
The leading assignee's record count outpaces the next several combined, concentrated around coapting-member and leaflet-approximation devices judging by the most-cited documents in this set.
A mid-tier cluster files steadily but narrowly
Fifth place holds 9 records and tenth place holds 4, showing a fairly even step-down rather than a sharp cliff, consistent with several specialised device makers each defending a narrower slice of the anchoring or annuloplasty mechanism space.
Cross-filing is rare and concentrated in academic-clinical pairs
Only six co-assignee pairs appear across the dataset, the strongest linking a hospital research group with a children's hospital medical centre, suggesting most commercial filers develop and file independently rather than through joint IP.
| Assignee | Recent year | YoY |
|---|---|---|
| Edwards Lifesciences Corp | 0 | — |
| Opus Medical Therapies LLC | 0 | — |
| HEART REPAIR TECH INC | 0 | — |
| Evalve | 0 | -100% |
| Kephalios | 0 | — |
| The Brigham & Women's Hospital Inc | 0 | — |
| The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services | 0 | — |
| MVRx Inc | 0 | — |
Where to take this analysis
The dataset points to a concentrated core and a thinner set of adjacent branches. The next steps depend on whether the goal is freedom-to-operate, licensing, or new device design.
Run a freedom-to-operate check on anchor placement claims
With the leader holding 31 of 119 records and most concentration sitting in A61F implant claims, any new anchoring mechanism should be checked against the leading assignees' device geometry claims specifically, not just the field broadly.
Explore this in EurekaTrack the 2021-2024 filing recovery as it publishes
The +100% rise from 2021 to 2024 is based on small counts and 2025-2026 data is still incomplete due to publication lag. Monitoring how this trend resolves over the next 18 months will clarify whether the recovery is broad or driven by one or two filers.
Explore this in EurekaScope the under-claimed branches before drafting
Lead-interference mitigation, imaging-guided placement and migration-correction tools show thinner representation than core implant claims. These are candidate areas for a first claim rather than a crowded one.
Explore this in EurekaCommon questions about this landscape
The assignee ranking for this dataset covers 25 companies, with the leader holding 31 of the 119 records in scope and the top five combined accounting for 74.8% of all records. The top ten assignees together cover the entire ranked set, meaning the remaining fifteen ranked companies each hold a comparatively small number of records. This points to a field where a handful of established medical device and hospital-affiliated filers set the pace, and later entrants are filing into already-dense claim territory, particularly around anchoring and coaptation mechanisms.
Filing activity peaked at 21 records in 2018, declined afterward, and has shown renewed growth from 1 filing in 2021 to 2 in 2024, a +100% rise over that three-year window. Counts for 2025 and 2026 are not yet complete because publication typically lags filing by around 18 months, so the most recent years understate actual activity. Based on complete-year data through 2024, the trend should be read as a recovery rather than a decline.
Implant and prosthesis claims under IPC class A61F appear in 97.5% of the 119 records in scope, making device geometry and anchoring mechanics the dominant claim area. Diagnosis and surgical technique claims (A61B) appear in 42.0% of records, and body-fluid handling devices (A61M) in 20.2%. Imaging (G06T) and sterilisation (A61L) classes are present but much smaller, each under 6% of records, suggesting these are secondary or supporting claim elements rather than primary battlegrounds.
The technology composition data shows imaging-related claims (G06T, 5.9% of records) and sterilisation-specific claims (A61L, 4.2%) are comparatively thin relative to the dominant implant class. Areas such as lead-interference mitigation for patients with concurrent pacing devices, imaging-guided anchor placement, and post-implant device migration correction show less concentrated coverage than core anchoring and coaptation claims. These are reasonable areas to investigate for a first claim, though a full freedom-to-operate search is needed before relying on this as a clearance signal.
US20250325371A1, filed by Condado, Jose A and published 23 October 2025, describes a catheter-based method for mitral and tricuspid annuloplasty that punctures the posterior sulcus, places anchor devices with ropes on either side of a central support point, and couples the resulting bars with a zipper mechanism to form a support structure. It is a method-plus-device claim rather than a pure implant claim, so it primarily constrains approaches using this specific puncture-and-zipper anchoring sequence rather than tricuspid repair generally. Designers using different anchoring or coaptation mechanisms, such as clip-based leaflet approximation, would need a separate review but are not automatically blocked by this filing.
Research Tricuspid Valve Interventions in depth with Eureka
Go past this page: query the whole tricuspid valve interventions corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.